key: cord-0798016-7qrcixu5 authors: Salehi, Mohammadreza; Khajavirad, Nasim; Seifi, Arash; Salahshour, Faeze; Jahanbin, Behnaz; Kazemizadeh, Hossein; Hashemi, Sayed Jamal; Dehghan Manshadi, Seyed Ali; Kord, Mohammad; Verweij, Paul E.; Khodavaisy, Sadegh title: Proven Aspergillus flavus pulmonary aspergillosis in a COVID‐19 patient: A case report and review of the literature date: 2021-03-02 journal: Mycoses DOI: 10.1111/myc.13255 sha: 7498c8847264ef1990d7e2b5ba2b875dab540ee8 doc_id: 798016 cord_uid: 7qrcixu5 Severe COVID‐19 patients complicated with aspergillosis are increasingly reported. We present a histopathological proven case of fatal COVID‐19–associated pulmonary aspergillosis (CAPA), due to Aspergillus flavus. This report and existing published literature indicate diagnostic challenges and poor outcomes of CAPA in ICU patients. Coronavirus disease 2019 (COVID -19) has been sweeping across the globe. Like severe influenza pneumonia, COVID-19 is associated with acute respiratory distress syndrome (ARDS), which might be considered a risk of fungal colonisation and infection of the respiratory tract. 1, 2 Mortality in severe COVID-19 cases is significant compared with non-severe infection cases due to the higher co-infection rate. 3 Unlike bacterial co-infections, the risk of fungal co-infections, including oropharyngeal candidiasis, invasive aspergillosis (IA), endemic mycoses, mucormycosis and fusariosis is notable in patients with severe COVID-19, despite the absence of classical well-defined host factors. [4] [5] [6] [7] [8] [9] [10] [11] [12] Possible explanations for the development of fungal co-infections include immune paralysis caused by COVID-19 infection-induced ARDS, diffuse alveolar damage with severe inflammatory exudation and lymphopenia. 13, 14 Preliminary reports showed 19-33% of severe COVID-19-associated pulmonary aspergillosis (CAPA) in ICU patients. 15, 16 Research findings strongly suggest that mechanically ventilated COVID-19 patients with longer duration of hospital admission should be systematically screened for Aspergillus infections. 15 Here, we describe CAPA in an immunocompetent patient and review the available literature on the subject. A 70-year-old man with a history of recent hospital admission due to SARS-CoV-2 infection with the diagnosis of exacerbation of viral pneumonia that was had been referred to Imam Khomeini Hospital complex Tehran, Iran. Imam Khomeini Hospital complex is the largest referral centre in the country, admitted 25,410 patients in 2020 alone. Time course of the patient is detailed in Figure 1 . In the previous hospitalisation, COVID-19 infection was confirmed by positive nasopharyngeal PCR and with more than 50% field involvement of both lungs on chest CT scan. At the first admission, he had received hydroxychloroquine 200 mg/PO/BID for 5 days, interferon beta-1 A/SC/every other day for 5 doses and dexamethasone 8 mg/IV/ daily according to the country guideline and had been discharged from the hospital after 12 days with a partial clinical recovery. However, after 3 days he was re-admitted with exacerbation of respiratory symptoms. On admission, his respiratory rate was 28 /min and Spo2 in room air was 80%. The patient's laboratory data showed lymphopenia (216/mL) and elevated inflammatory markers (ESR: 30 mm/1hr, CRP: 40 mg/L, ferritin: 3,000 ng/ mL, lactic acid dehydrogenase: 440 U/L and marked elevated D-dimer: 2,572 ng/mL). Other laboratory results included WBC: 7,200/mL, PMN: 95.5%, Hb: 16 gr/dL, PLT: 176,000/mL and creatinine: 1.1 mg/dL. SARS-CoV-2 PCR test was still positive at the time of his re-admission. Chest CT scan (Figure 2A ) revealed multilobar peripheral ground-glass opacities compatible with COVID-19 pneumonia (>50% involvement). Evaluation for heart diseases was negative (normal echocardiography). According to the progression F I G U R E 1 Timeline of the patient with COVID-19-associated pulmonary aspergillosis F I G U R E 2 A, Contrast-enhanced computed tomography chest showing multi-lobar peripheral ground-glass opacities; B, the reduced ground-glass opacities and three new foci of peripheral wedge-shaped air-space opacities with reverse halo developed in the right middle lobe; C, the yellow arrows depict the foci of bronchial wall defects. The green arrow shows sloughed debris mimicking invasive aspergillosis Unfortunately, the patient died after 12 hours with cardiac arrest. An autopsy was not performed. The English literature was reviewed for published CAPA cases using search terms "corona", "COVID-19", "aspergillosis", "CAPA" and "fungal". A total of 175 CAPA cases were found and details are presented in Table 1 . Although variable case definitions were used, only 7 (4%) cases were classified as proven CAPA. Although secondary bacterial and viral infections are reported at low frequency in COVID-19 patients, high frequencies of CAPA cases are published in association with COVID-19 in the ICU. Case series from the Netherlands, Germany and France reported CAPA 19%, 26% and 33% of patients with severe COVID-19 pneumonia, respectively. 5 Although lower rates were reported from Switzerland (3.8%) and China (7%). 18, 19 A major challenge remains diagnosing CAPA as the performance of diagnostic Aspergillus biomarkers remains suboptimal. Serum galactomannan (GM) detection is commonly negative even in patients with proven CAPA. 20 In our reviewed cases, serum GM was performed in 73 of 183 CAPA patients (39.8%), while GM was detected in only 19 (26%) patients (Table 1) (Table S1) Iran. 17, 33, 34 In conclusion, recovery of Aspergillus species in a critically-ill COVID-19 patient should not be ignored, but requires a diagnostic workup despite suboptimal performance of relevant biomarkers. The new consensus definitions and reporting of proven CAPA cases will help to further understand the pathophysiology of IA in patients with COVID-19 and help to optimise clinical management. This study has been funded and supported by the Tehran University of Medical Sciences (TUMS), Grant No. 99-1-99-47198. The authors declare no conflict of interest. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study Diagnosing COVID-19-associated pulmonary aspergillosis Dysregulation of immune response in patients with COVID-19 in Wuhan China Pulmonary aspergillosis in critically ill patients with Coronavirus Disease 2019 (COVID-19) COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study Azole-Resistant COVID-19-associated pulmonary aspergillosis in an immunocompetent host: a case report Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: Species identification and antifungal susceptibility pattern COVID-19 Associated Invasive Pulmonary Aspergillosis: Diagnostic and Therapeutic Challenges Coronavirus disease 2019 (COVID-19) in a patient with disseminated Histoplasmosis and HIV-A case report from Argentina and literature review Mucormycosis with orbital compartment syndrome in a patient with COVID-19 Invasive pulmonary fusariosis in an immunocompetent critically ill patient with severe COVID-19 Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from Iran Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study High prevalence of putative invasive pulmonary aspergillosis in critically ill COVID-19 patients COVID-19 associated pulmonary aspergillosis In vitro activities of five antifungal agents against 199 clinical and environmental isolates of Aspergillus flavus, an opportunistic fungal pathogen Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series COVID-19 associated invasive aspergillosis: data from the UK National Mycology Reference Laboratory COVID-19-associated invasive pulmonary aspergillosis Bronchoscopy safety precautions for diagnosing COVID-19 associated pulmonary aspergillosis-A simulation study The use of bronchoscopy during the COVID-19 pandemic: CHEST/AABIP guideline and expert panel report Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline Late histopathologic characteristics of critically ill COVID-19 patients: Different phenotypes without evidence of invasive aspergillosis, a case series A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU Classification of aerosolgenerating procedures: a rapid systematic review Review of influenzaassociated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity Defining and managing COVID-19 associated pulmonary aspergillosis: The 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2020 Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America Predominance of nonfumigatus Aspergillus species among patients suspected to pulmonary aspergillosis in a tropical and subtropical region of the Middle East Genotyping of clinical and environmental Aspergillus flavus isolates from Iran using microsatellites Aspergillosis complicating severe coronavirus disease Isolation of Aspergillus spp. in respiratory samples of patients with COVID-19 in a Spanish tertiary care hospital COVID-19-associated pulmonary aspergillosis Incidence, risk factors, timing and outcome of influenza versus COVID-19 associated putative invasive aspergillosis Putative invasive pulmonary aspergillosis in critically ill patients with COVID-19: An observational study from New York City Invasive pulmonary aspergillosis in severe COVID-19 pneumonia Clinical and virological data of the first cases of COVID-19 in Europe: a case series Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: A diagnostic challenge Invasive pulmonary aspergillosis complicating COVID-19 in the ICU-A case report. Med Mycol Case Rep Confirmed Invasive Pulmonary Aspergillosis and COVID-19: the value of postmortem findings to support antemortem management COVID-19 associated pulmonary aspergillosis (CAPA): An Australian case report. Med Mycol Case Rep Dynamic immune response profiles and recovery of a COVID-19 patient with coinfection of Aspergillus fumigatus and other baseline diseases: a case report Fatal aspergillosis complicating severe SARS-CoV-2 infection: a case report Fatal invasive pulmonary Aspergillosis in COVID-19 patient with Acute Myeloid Leukemia in Iran Recovery of a triazole-resistant Aspergillus fumigatus in respiratory specimen of COVID-19 patient in ICU-A case report. Med Mycol Case Rep Ventilator-associated pneumonia involving Aspergillus flavus in a patient with coronavirus disease 2019 (COVID-19) from Argentina. Med mycol case rep Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium